SCHEMBL3210253

SCHEMBL3210253

CS(=O)(=O)Nc1cccc(N(Cc2cncs2)c2ccc(OC(F)F)c(OC(F)F)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.41
NR3C2 P08235 4/20 0.38
PGR P06401 1/20 0.35
AR P10275 1/20 0.35
PDE4D Q08499 2/20 0.35
CYP17A1 P05093 2/20 0.35
CYP1A2 P05177 3/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2D6 P10635 3/20 0.35
CYP2C19 P33261 3/20 0.35
HSD17B10 Q99714 3/20 0.35
CYP2C9 P11712 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
HRH4 Q9H3N8 1/20 0.34
KCNA5 P22460 1/20 0.34
KCNH2 Q12809 1/20 0.34
TSHR P16473 2/20 0.34
HTT P42858 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3202234 0.92 ADRA2A (0.36) NR3C1CYP17A1HRH4HTTALDH1A1
SCHEMBL3207210 0.86 TAAR1 (0.43) PDE4DHRH4KCNA5PDE4APDE4B
SCHEMBL3203668 0.85 ADRB3 (0.36) PDE4DCYP17A1HRH4ALDH1A1ADRB3
SCHEMBL3204654 0.83 HRH4 (0.33) NR3C2PDE4DHRH4PDE4APDE4B
SCHEMBL3212622 0.80 PDE4A (0.33) HRH4PDE4A
SCHEMBL3193120 0.80 ACLY (0.33) HRH4PDE4B
SCHEMBL3192323 0.80 HRH4 (0.33) HRH4PDE4APDE4B
SCHEMBL3194668 0.80 RORC (0.35) HRH4
SCHEMBL3214943 0.79 HRH4 (0.33) HRH4HTTKMT2A
SCHEMBL3123327 0.79 PDE4A (0.38) PDE4DTDP1KMT2APDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B NR3C1 2018/4885NR3C2 1266/4885PGR 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.